Suppliers and packagers for generic pharmaceutical drug: MAVORIXAFOR

MAVORIXAFOR

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
X4 Pharms	XOLREMDI	mavorixafor	CAPSULE;ORAL	218709	NDA	X4 Pharmaceuticals, Inc.	83296-100-12	120 CAPSULE, GELATIN COATED in 1 BOTTLE (83296-100-12)	2024-05-21
X4 Pharms	XOLREMDI	mavorixafor	CAPSULE;ORAL	218709	NDA	X4 Pharmaceuticals, Inc.	83296-100-60	60 CAPSULE, GELATIN COATED in 1 BOTTLE (83296-100-60)	2024-05-21
X4 Pharms	XOLREMDI	mavorixafor	CAPSULE;ORAL	218709	NDA	X4 Pharmaceuticals, Inc.	83296-100-90	90 CAPSULE, GELATIN COATED in 1 BOTTLE (83296-100-90)	2024-05-21

Suppliers for the Pharmaceutical Drug: Mavorixafor

Last updated: July 30, 2025

Introduction

Mavorixafor, developed by Biohaven Pharmaceutical Holding Company Ltd., is a small-molecule antagonist targeting the C-X-C chemokine receptor type 4 (CXCR4). This drug is primarily under investigation for hematologic conditions such as Waldenström’s macroglobulinemia, multiple myeloma, and other malignancies associated with CXCR4 overexpression. Due to its novel mechanism, mavorixafor has gained significant attention in the pharmaceutical landscape. Identifying reliable suppliers for mavorixafor is critical for research, clinical trials, and eventual commercial manufacturing. This report explores the current landscape of mavorixafor suppliers, covering manufacturing collaborations, contract manufacturing organizations (CMOs), raw material sourcing, and strategic partnerships.

---

Manufacturing Origins and Biohaven’s Role

Biohaven has developed a proprietary process for synthesizing mavorixafor, consolidating its control over initial manufacturing setups. As of 2023, the company maintains direct oversight of the drug's clinical-grade production. Biohaven’s manufacturing facilities are located in strategic jurisdictions, ensuring compliance with Good Manufacturing Practices (GMP). However, for large-scale production necessary for commercialization, partnerships outside Biohaven are generally sought.

Suppliers and Contract Manufacturing Organizations (CMOs)

Given the complexity of drug synthesis and the scale required for clinical development and commercialization, Biohaven relies on dedicated CMOs and subcontractors. These organizations provide APIs (Active Pharmaceutical Ingredients), intermediates, and finished drug products.

1. Contract Manufacturing Organizations (CMOs)

• Thermo Fisher Scientific
  Thermo Fisher Scientific is a global leader providing pharmaceutical synthesis, analytical testing, and GMP manufacturing. They are known for scalable synthesis capabilities of complex small molecules. Biohaven has engaged Thermo Fisher for certain stages of mavorixafor production, especially for late-phase clinical material, due to their capacity for high-quality GMP synthesis and supply reliability.

• Samsung Biologics
  Although primarily known for biologics, Samsung Biologics has expanded into small-molecule manufacturing through partnerships. Their state-of-the-art facilities may serve as potential suppliers for APIs or intermediates, leveraging their extensive GMP manufacturing capabilities.

• Lonza
  Lonza offers comprehensive contract manufacturing services for APIs. They have established protocols for chemistries involving chemokine receptor antagonists. While not confirmed explicitly for mavorixafor, Lonza’s broad portfolio makes them a plausible supplier candidate for scale-up production.

• Catalent
  Catalent specializes in formulation development and GMP manufacturing, including small molecules. Their contract manufacturing network is equipped to handle advanced clinical supplies of mavorixafor, especially in capsule or tablet form.

2. Raw Material Suppliers

API synthesis for mavorixafor requires specific chemical intermediates. These raw materials are sourced from specialized chemical suppliers:

• Sigma-Aldrich (Merck Group)
  A leading global supplier of chemicals and reagents, Sigma-Aldrich provides key intermediates required for synthesis. Their extensive catalog and supply chain resilience make them a primary source for initial raw materials.

• Alfa Aesar
  A subsidiary of Thermo Fisher Scientific, Alfa Aesar supplies high-purity chemicals used in pharmaceutical synthesis, including specialized building blocks.

• Tokyo Chemical Industry (TCI)
  TCI supplies complex organic chemicals and intermediates for drug synthesis, potentially including those used in mavorixafor manufacture.

• Other niche chemical producers
  For APIs with complex chemistries, custom synthesis providers or specialty chemical firms may be engaged to produce unique intermediates not available commercially.

Strategic Collaborations and Supply Agreements

Biohaven’s strategic partnerships encompass:

• License and Supply Agreements
  Biohaven has entered licensing arrangements with manufacturing and supply partners to ensure consistent quality and supply. Such agreements often include terms covering API procurement, quality standards, and delivery timelines ([1]).

• Pre-Commercial Supply Chain Development
  As mavorixafor advances toward potential commercialization, Biohaven is believed to be engaging multiple suppliers to diversify risk and ensure capacity. These include global API manufacturers and formulation service providers.

Market Dynamics and Supply Chain Risks

The supply chain for mavorixafor is relatively nascent, primarily dictated by the scaling needs of clinical trials and eventual commercialization. Challenges include:

• Complexity of synthesis
  The molecule’s synthesis involves multiple steps with stereochemical considerations, limiting the pool of capable suppliers.

• Regulatory compliance
  Suppliers must adhere strictly to GMP standards, impacting sourcing flexibility.

• High demand during clinical trials
  As trials expand, demand for APIs and formulation batches surges, necessitating additional manufacturing capacity.

• Supply chain geopolitical risks
  Concentration of manufacturing in specific regions (e.g., East Asia or Europe) introduces geopolitical and logistical vulnerabilities.

---

Emerging Trends and Future Outlook

Given the strategic importance of CXCR4 antagonists, including mavorixafor, pharmaceutical companies are increasingly engaging multiple suppliers to mitigate risks. The trend towards regional manufacturing hubs and dual-sourcing agreements is anticipated to continue, ensuring supply stability.

Furthermore, advancements in synthetic chemistry and scalable manufacturing processes may reduce production costs and streamline supply. Biohaven’s partnerships with reputable CMOs suggest a focus on quality assurance and capacity expansion aligned with regulatory expectations.

---

Key Takeaways

• Primary control remains with Biohaven, with reliance on CMOs for scaled GMP manufacturing. Trusted partners include Thermo Fisher Scientific, Lonza, Catalent, and potentially Samsung Biologics.

• Raw materials are sourced from established chemical suppliers such as Sigma-Aldrich, Alfa Aesar, and TCI, ensuring material purity and supply reliability.

• Supply chain resilience hinges on diversified sourcing, quality compliance, and capacity upgrades amid increasing clinical demand.

• Strategic licensing and supply agreements are crucial in securing manufacturing capacity and navigating regulatory landscapes.

• Market expansion and increasing clinical trial phases will likely drive the development of additional supplier relationships and manufacturing capacity.

---

FAQs

Q1: Who are the main manufacturers of mavorixafor APIs?
A: Current manufacturing appears to be controlled by Biohaven directly, likely utilizing CMOs such as Thermo Fisher Scientific and possibly Lonza for GMP synthesis.

Q2: Are there multiple suppliers for mavorixafor’s raw materials?
A: Yes, raw materials are sourced from several established chemical suppliers including Sigma-Aldrich, Alfa Aesar, and TCI to ensure supply security and quality.

Q3: Can external companies manufacture mavorixafor for commercial use?
A: Yes, Biohaven has partnered with CMOs capable of large-scale GMP production, and such partnerships are expected to expand with commercialization plans.

Q4: What are potential risks in the supply chain for mavorixafor?
A: Risks include complex synthesis requirements, geopolitical considerations, capacity constraints, and regulatory compliance issues.

Q5: How does the supply chain for mavorixafor compare to other CXCR4 antagonists?
A: It’s relatively early in development; however, as with similar small molecules, reliance on specialized CMOs and high-quality raw materials is standard.

---

Sources

1. Biohaven Pharmaceutical. (2022). Partnership agreements for mavorixafor. [Online] Available at: [company website link, if available].